Compare ALV & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALV | RDY |
|---|---|---|
| Founded | 1953 | 1984 |
| Country | Sweden | India |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.6B |
| IPO Year | 1997 | N/A |
| Metric | ALV | RDY |
|---|---|---|
| Price | $120.69 | $13.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $133.45 | $16.90 |
| AVG Volume (30 Days) | 586.1K | ★ 1.2M |
| Earning Date | 01-30-2026 | 01-22-2026 |
| Dividend Yield | ★ 2.83% | 0.51% |
| EPS Growth | ★ 25.57 | 9.95 |
| EPS | ★ 9.69 | 0.79 |
| Revenue | ★ $10,614,000,000.00 | $3,851,623,984.00 |
| Revenue This Year | $4.73 | $6.16 |
| Revenue Next Year | $4.40 | $2.57 |
| P/E Ratio | ★ $12.40 | $17.89 |
| Revenue Growth | 0.85 | ★ 14.10 |
| 52 Week Low | $75.49 | $12.26 |
| 52 Week High | $129.54 | $16.17 |
| Indicator | ALV | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 49.65 |
| Support Level | $118.76 | $13.90 |
| Resistance Level | $122.90 | $14.16 |
| Average True Range (ATR) | 2.31 | 0.15 |
| MACD | 0.33 | -0.00 |
| Stochastic Oscillator | 67.32 | 56.64 |
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.